Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer

by Brad Rybinski, H. Dean Hosgood, Sara L. Wiener, Daniel A. Weiser, Daniel A. Weiser
Published 2020-11-01

XPO1 inhibition with selinexor synergizes with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB

by Basia Galinski, Marcus Luxemburg, Yosef Landesman, Bruce Pawel, Katherine J. Johnson, Stephen R. Master, Kevin W. Freeman, David M. Loeb, Jean M. Hébert, Daniel A. Weiser
Published 2021-08-01

Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children’s Onco...

by Michael D. Kinnaman, Chong Zhu, Daniel A. Weiser, Sana Mohiuddin, Pooja Hingorani, Michael Roth, Jonathan Gill, Katherine A. Janeway, Richard Gorlick, Stephen L. Lessnick, Patrick J. Grohar
Published 2020-01-01

Skp2 depletion reduces tumor-initiating properties and promotes apoptosis in synovial sarcoma

by Jichuan Wang, Kenji Sato, Ed O'Donnell, Amit Singla, Simon Yaguare, Osama Aldahamsheh, Brian Batko, Hasibagan Borjihan, Janet Tingling, Jinghang Zhang, Daniel A. Weiser, David M. Loeb, Richard Gorlick, Edward L. Schwartz, Rui Yang, Xiaolin Zi, Hongling Zhao, David S. Geller, Bang H. Hoang
Published 2020-10-01